Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-S: Rollover Study for Anifrolumab
NCT07691970Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Primary completion
- Dec 2032
- Countries
- 35
01
Overview
A Phase 3 trial of anifrolumab in systemic sclerosis (SSc), cutaneous lupus erythematosus (CLE), myopathies, systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Aug 2026; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic sclerosis (SSc)cutaneous lupus erythematosus (CLE)myopathiessystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07691970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691970.